Cas12a chRDNA-mediated in vivo genome editing for high specificity functional gene disruption.

Cas12a chRDNA genome editing achieves near-complete target gene disruption with high specificity and no detectable off-target effects in vivo.

• Why it matters: Precise genome editing is crucial for treating inherited diseases like familial hypercholesterolemia and transthyretin amyloidosis, but off-target effects pose safety concerns.
• What they did: The study used lipid nanoparticle delivery of Cas12a mRNA with CRISPR hybrid RNA-DNA guides to target three genes in mice, achieving high editing efficiency with minimal off-target activity.
• The result: This approach significantly reduced plasma proteins and cholesterol levels without toxicity, demonstrating a safe and effective method for in vivo genome editing applications.